The role of omega-3 polyunsaturated fatty acid supplementation in the management of type 2 diabetes mellitus: A narrative review

C. Itsiopoulos, W. Marx, H. L. Mayr, O. A. Tatucu-Babet, S. R. Dash, E. S. George, G. L. Trakman, J. T. Kelly, C. J. Thomas, L. Brazionis

Research output: Contribution to journalArticleResearchpeer-review

4 Citations (Scopus)
70 Downloads (Pure)

Abstract

Background: Type 2 Diabetes Mellitus (T2DM) poses a significant health and financial burden to individuals and healthcare systems. Omega-3 polyunsaturated fatty acids (PUFA) possess numerous properties (e.g. anti-inflammatory, anti-thrombotic, anti-lipidemic) that may be beneficial in the management of T2DM and its complications. Methods: In this narrative review, we discuss the potential mechanisms, clinical evidence-base, and practical considerations regarding the use of omega-3 PUFA supplementation for the management of glycaemic control and common comorbid conditions, including diabetic nephropathy and retinopathy, liver disease, cognition and mental health, and cardiometabolic disease. Results/conclusion: Omega-3 PUFA supplementation is generally well-tolerated and does not appear to be contraindicated for patients on anticoagulant therapy; however, uncertainty persists regarding the purity and stability of commercial omega-3 PUFA products. Despite promising animal studies, the current clinical evidence for the use of omega-3 supplementation for the management of T2DM and associated conditions is both limited and conflicting. Results from existing clinical trials do not support the use of omega-3 PUFA for glycaemic control and there are limited studies in T2DM populations to support the use of omega-3 PUFAs for associated complications of diabetes. Possible contributors to the conflicting evidence base are study design issues, such as inadequate intervention period, sample size, omega 3 supplement dose, variations in the EPA to DHA ratio and clinical heterogeneity among diabetic populations.

Original languageEnglish
Pages (from-to)42-51
Number of pages10
JournalJournal of Nutrition and Intermediary Metabolism
Volume14
Early online date12 Mar 2018
DOIs
Publication statusPublished - 1 Dec 2018

Fingerprint

Omega-3 Fatty Acids
Unsaturated Fatty Acids
noninsulin-dependent diabetes mellitus
omega-3 fatty acids
Type 2 Diabetes Mellitus
glycemic control
diabetic retinopathy
diabetic nephropathy
mental health
anticoagulants
Diabetic Nephropathies
liver diseases
Diabetic Retinopathy
Diabetes Complications
anti-inflammatory activity
cognition
purity
Sample Size
Anticoagulants
health services

Cite this

Itsiopoulos, C. ; Marx, W. ; Mayr, H. L. ; Tatucu-Babet, O. A. ; Dash, S. R. ; George, E. S. ; Trakman, G. L. ; Kelly, J. T. ; Thomas, C. J. ; Brazionis, L. / The role of omega-3 polyunsaturated fatty acid supplementation in the management of type 2 diabetes mellitus : A narrative review. In: Journal of Nutrition and Intermediary Metabolism. 2018 ; Vol. 14. pp. 42-51.
@article{d0f2568fc2d74b47bb0fad144003c886,
title = "The role of omega-3 polyunsaturated fatty acid supplementation in the management of type 2 diabetes mellitus: A narrative review",
abstract = "Background: Type 2 Diabetes Mellitus (T2DM) poses a significant health and financial burden to individuals and healthcare systems. Omega-3 polyunsaturated fatty acids (PUFA) possess numerous properties (e.g. anti-inflammatory, anti-thrombotic, anti-lipidemic) that may be beneficial in the management of T2DM and its complications. Methods: In this narrative review, we discuss the potential mechanisms, clinical evidence-base, and practical considerations regarding the use of omega-3 PUFA supplementation for the management of glycaemic control and common comorbid conditions, including diabetic nephropathy and retinopathy, liver disease, cognition and mental health, and cardiometabolic disease. Results/conclusion: Omega-3 PUFA supplementation is generally well-tolerated and does not appear to be contraindicated for patients on anticoagulant therapy; however, uncertainty persists regarding the purity and stability of commercial omega-3 PUFA products. Despite promising animal studies, the current clinical evidence for the use of omega-3 supplementation for the management of T2DM and associated conditions is both limited and conflicting. Results from existing clinical trials do not support the use of omega-3 PUFA for glycaemic control and there are limited studies in T2DM populations to support the use of omega-3 PUFAs for associated complications of diabetes. Possible contributors to the conflicting evidence base are study design issues, such as inadequate intervention period, sample size, omega 3 supplement dose, variations in the EPA to DHA ratio and clinical heterogeneity among diabetic populations.",
author = "C. Itsiopoulos and W. Marx and Mayr, {H. L.} and Tatucu-Babet, {O. A.} and Dash, {S. R.} and George, {E. S.} and Trakman, {G. L.} and Kelly, {J. T.} and Thomas, {C. J.} and L. Brazionis",
year = "2018",
month = "12",
day = "1",
doi = "10.1016/j.jnim.2018.02.002",
language = "English",
volume = "14",
pages = "42--51",
journal = "Journal of Nutrition and Intermediary Metabolism",
issn = "2352-3859",
publisher = "Elsevier BV",

}

The role of omega-3 polyunsaturated fatty acid supplementation in the management of type 2 diabetes mellitus : A narrative review. / Itsiopoulos, C.; Marx, W.; Mayr, H. L.; Tatucu-Babet, O. A.; Dash, S. R.; George, E. S.; Trakman, G. L.; Kelly, J. T.; Thomas, C. J.; Brazionis, L.

In: Journal of Nutrition and Intermediary Metabolism, Vol. 14, 01.12.2018, p. 42-51.

Research output: Contribution to journalArticleResearchpeer-review

TY - JOUR

T1 - The role of omega-3 polyunsaturated fatty acid supplementation in the management of type 2 diabetes mellitus

T2 - A narrative review

AU - Itsiopoulos, C.

AU - Marx, W.

AU - Mayr, H. L.

AU - Tatucu-Babet, O. A.

AU - Dash, S. R.

AU - George, E. S.

AU - Trakman, G. L.

AU - Kelly, J. T.

AU - Thomas, C. J.

AU - Brazionis, L.

PY - 2018/12/1

Y1 - 2018/12/1

N2 - Background: Type 2 Diabetes Mellitus (T2DM) poses a significant health and financial burden to individuals and healthcare systems. Omega-3 polyunsaturated fatty acids (PUFA) possess numerous properties (e.g. anti-inflammatory, anti-thrombotic, anti-lipidemic) that may be beneficial in the management of T2DM and its complications. Methods: In this narrative review, we discuss the potential mechanisms, clinical evidence-base, and practical considerations regarding the use of omega-3 PUFA supplementation for the management of glycaemic control and common comorbid conditions, including diabetic nephropathy and retinopathy, liver disease, cognition and mental health, and cardiometabolic disease. Results/conclusion: Omega-3 PUFA supplementation is generally well-tolerated and does not appear to be contraindicated for patients on anticoagulant therapy; however, uncertainty persists regarding the purity and stability of commercial omega-3 PUFA products. Despite promising animal studies, the current clinical evidence for the use of omega-3 supplementation for the management of T2DM and associated conditions is both limited and conflicting. Results from existing clinical trials do not support the use of omega-3 PUFA for glycaemic control and there are limited studies in T2DM populations to support the use of omega-3 PUFAs for associated complications of diabetes. Possible contributors to the conflicting evidence base are study design issues, such as inadequate intervention period, sample size, omega 3 supplement dose, variations in the EPA to DHA ratio and clinical heterogeneity among diabetic populations.

AB - Background: Type 2 Diabetes Mellitus (T2DM) poses a significant health and financial burden to individuals and healthcare systems. Omega-3 polyunsaturated fatty acids (PUFA) possess numerous properties (e.g. anti-inflammatory, anti-thrombotic, anti-lipidemic) that may be beneficial in the management of T2DM and its complications. Methods: In this narrative review, we discuss the potential mechanisms, clinical evidence-base, and practical considerations regarding the use of omega-3 PUFA supplementation for the management of glycaemic control and common comorbid conditions, including diabetic nephropathy and retinopathy, liver disease, cognition and mental health, and cardiometabolic disease. Results/conclusion: Omega-3 PUFA supplementation is generally well-tolerated and does not appear to be contraindicated for patients on anticoagulant therapy; however, uncertainty persists regarding the purity and stability of commercial omega-3 PUFA products. Despite promising animal studies, the current clinical evidence for the use of omega-3 supplementation for the management of T2DM and associated conditions is both limited and conflicting. Results from existing clinical trials do not support the use of omega-3 PUFA for glycaemic control and there are limited studies in T2DM populations to support the use of omega-3 PUFAs for associated complications of diabetes. Possible contributors to the conflicting evidence base are study design issues, such as inadequate intervention period, sample size, omega 3 supplement dose, variations in the EPA to DHA ratio and clinical heterogeneity among diabetic populations.

UR - http://www.scopus.com/inward/record.url?scp=85044172623&partnerID=8YFLogxK

U2 - 10.1016/j.jnim.2018.02.002

DO - 10.1016/j.jnim.2018.02.002

M3 - Article

VL - 14

SP - 42

EP - 51

JO - Journal of Nutrition and Intermediary Metabolism

JF - Journal of Nutrition and Intermediary Metabolism

SN - 2352-3859

ER -